Jan 05, 2017
AstraZeneca and APT Therapeutics have signed a research collaboration, option, and asset deal focused on the development of APT’s lead human recombinant apyrase therapy, APT102, for the treatment of thrombotic diseases. Under the terms of the agreement, AstraZeneca will make an undisclosed upfront cash payment to APT, which will also be eligible to receive future development milestones. AstraZeneca will carry out all clinical trials with APT102 for the indications of heart attack and stroke.
According to APT, studies in animal models of stroke and heart attack have shown that APT102 reduces clot formation without causing bleeding and can also reduce bleeding associated with current antithrombotics, unlike existing antithrombotic drugs, which can increase bleeding risk.
Animal studies also indicate that APT102 starts to inhibit platelet activation and aggregation almost immediately after intravenous administration and continues to work for at least 24 hours after a single injection.
Marcus Schindler, VP for cardiovascular and metabolic diseases, innovative medicines, and early development at AstraZeneca, said: “The science behind APT102 provides a differentiated opportunity for cardio protection during the critical acute phase after a heart attack or stroke.”
Ridong Chen, Ph.D., president and CEO of APT Therapeutics, said: “By combining their [AstraZeneca’s] strengths with our own research and development expertise in human apyrase therapy, we have a great opportunity to develop a breakthrough drug that will safely and substantially improve the lives of millions of patients worldwide.”